A U.S. Post-Approval Study of the SYNERGY 4.50/5.00 mm Everolimus-Eluting Platinum Chromium Coronary Stent System (Evolve 4.5/5.0)
Latest Information Update: 20 Dec 2023
At a glance
- Drugs Everolimus (Primary)
- Indications Atherosclerosis; Coronary artery disease; Coronary artery restenosis
- Focus Therapeutic Use
- Sponsors Boston Scientific Corporation
- 13 Dec 2023 Status changed from active, no longer recruiting to completed.
- 10 Dec 2020 Status changed from recruiting to active, no longer recruiting.
- 10 Dec 2020 Planned End Date changed from 1 May 2023 to 1 Dec 2023.